221 related articles for article (PubMed ID: 16183066)
21. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G
Atherosclerosis; 2008 Feb; 196(2):659-66. PubMed ID: 17765244
[TBL] [Abstract][Full Text] [Related]
22. Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.
Sjouke B; Defesche JC; Hartgers ML; Wiegman A; Roeters van Lennep JE; Kastelein JJ; Hovingh GK
J Clin Lipidol; 2016; 10(6):1462-1469. PubMed ID: 27919364
[TBL] [Abstract][Full Text] [Related]
23. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review.
Mohd Nor NS; Al-Khateeb AM; Chua YA; Mohd Kasim NA; Mohd Nawawi H
BMC Pediatr; 2019 Apr; 19(1):106. PubMed ID: 30975109
[TBL] [Abstract][Full Text] [Related]
24. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic.
Tosi I; Toledo-Leiva P; Neuwirth C; Naoumova RP; Soutar AK
Atherosclerosis; 2007 Sep; 194(1):102-11. PubMed ID: 17094996
[TBL] [Abstract][Full Text] [Related]
25. Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient.
Al-Allaf FA; Alashwal A; Abduljaleel Z; Taher MM; Bouazzaoui A; Abalkhail H; Al-Allaf AF; Athar M
Acta Biochim Pol; 2017; 64(1):75-79. PubMed ID: 27878139
[TBL] [Abstract][Full Text] [Related]
26. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
[TBL] [Abstract][Full Text] [Related]
27. Additive Effect of
Marmontel O; Abou-Khalil Y; Bluteau O; Cariou B; Carreau V; Charrière S; Divry E; Gallo A; Moulin P; Paillard F; Peretti N; Rabès JP; Varret M; Carrié A; Di Filippo M
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):e270-e278. PubMed ID: 37128917
[TBL] [Abstract][Full Text] [Related]
28. The genetic spectrum of familial hypercholesterolemia in Pakistan.
Ahmed W; Whittall R; Riaz M; Ajmal M; Sadeque A; Ayub H; Qamar R; Humphries SE
Clin Chim Acta; 2013 Jun; 421():219-25. PubMed ID: 23535506
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
[TBL] [Abstract][Full Text] [Related]
30. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
Hori M; Ohta N; Takahashi A; Masuda H; Isoda R; Yamamoto S; Son C; Ogura M; Hosoda K; Miyamoto Y; Harada-Shiba M
Atherosclerosis; 2019 Oct; 289():101-108. PubMed ID: 31491741
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Tada H; Nakanishi C; Mori M; Yamagishi M; Inazu A; Koizumi J;
Atherosclerosis; 2011 Feb; 214(2):404-7. PubMed ID: 21146822
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.
Bertolini S; Pisciotta L; Rabacchi C; Cefalù AB; Noto D; Fasano T; Signori A; Fresa R; Averna M; Calandra S
Atherosclerosis; 2013 Apr; 227(2):342-8. PubMed ID: 23375686
[TBL] [Abstract][Full Text] [Related]
33. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.
Naoumova RP; Tosi I; Patel D; Neuwirth C; Horswell SD; Marais AD; van Heyningen C; Soutar AK
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2654-60. PubMed ID: 16224054
[TBL] [Abstract][Full Text] [Related]
34. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
35. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
37. APOE p.Leu167del mutation in familial hypercholesterolemia.
Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
[TBL] [Abstract][Full Text] [Related]
38. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A
Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716
[TBL] [Abstract][Full Text] [Related]
39. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
[TBL] [Abstract][Full Text] [Related]
40. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
